LENZ Therapeutics (LENZ) Cash from Operations (2020 - 2026)
LENZ Therapeutics (LENZ) reported Cash from Operations of 33582000.0 for Q1 2026, down 109.25% year-over-year from 363178920.49 in Q1 2025, and down 1.69% on a QoQ basis from 33025000.0 in Q4 2025.
LENZ Therapeutics (LENZ) has 7 years of Cash from Operations data on file, last reported at 33582000.0 in Q1 2026.
- Quarterly Cash from Operations fell 109.25% year-over-year to 33582000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 86703000.0 (down 68.35% YoY) and the FY2025 annual result came in at 69170000.0, down 16.47% from the prior year.
- Cash from Operations slipped to 33582000.0 in Q1 2026 per LENZ's latest filing, from 33025000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 8588000.0 in Q3 2025 and bottomed at 33582000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 16049000.0 (2025), against an average of 18264882.35.
- The widest annual swing landed in 2024, when Cash from Operations soared 56.71%; it then slumped 263.79% in 2025.
- Tracing LENZ's Cash from Operations over 5 years: stood at 22429000.0 in 2022, then advanced by 6.5% to 20970000.0 in 2023, then soared by 56.71% to 9078000.0 in 2024, then tumbled by 263.79% to 33025000.0 in 2025, then dropped by 1.69% to 33582000.0 in 2026.
- Per Business Quant, the three latest LENZ Cash from Operations figures stand at 33582000.0 (Q1 2026), 33025000.0 (Q4 2025), and 8588000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | -33.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.58 Mn |
| Mar 31, 2026 | -33.58 Mn |
| Dec 31, 2025 | -33.03 Mn |
| Dec 31, 2025 | -33.03 Mn |
| Sep 30, 2025 | -8.59 Mn |
| Sep 30, 2025 | -8.59 Mn |
| Jun 30, 2025 | -11.51 Mn |
| Jun 30, 2025 | -11.51 Mn |
| Mar 31, 2025 | -16.05 Mn |
| Mar 31, 2025 | -16.05 Mn |
| Dec 31, 2024 | -9.08 Mn |
| Dec 31, 2024 | -9.08 Mn |
| Sep 30, 2024 | -10.58 Mn |
| Sep 30, 2024 | -10.58 Mn |
| Jun 30, 2024 | -15.80 Mn |
| Jun 30, 2024 | -15.80 Mn |
| Mar 31, 2024 | -23.94 Mn |
| Mar 31, 2024 | -23.94 Mn |
| Dec 31, 2023 | -20.97 Mn |
| Dec 31, 2023 | -20.97 Mn |
| Sep 30, 2023 | -13.09 Mn |
| Sep 30, 2023 | -13.09 Mn |
| Jun 30, 2023 | -13.52 Mn |
| Jun 30, 2023 | -13.52 Mn |
| Mar 31, 2023 | -12.80 Mn |
| Mar 31, 2023 | -12.80 Mn |
| Dec 31, 2022 | -22.43 Mn |
| Dec 31, 2022 | -22.43 Mn |
| Sep 30, 2022 | -22.22 Mn |
| Sep 30, 2022 | -22.22 Mn |
| Jun 30, 2022 | -22.09 Mn |
| Jun 30, 2022 | -22.09 Mn |
| Mar 31, 2022 | -21.24 Mn |
| Mar 31, 2022 | -21.24 Mn |
| Dec 31, 2021 | -15.59 Mn |
| Dec 31, 2021 | -15.59 Mn |
| Sep 30, 2021 | -15.42 Mn |
| Sep 30, 2021 | -15.42 Mn |
| Jun 30, 2021 | -13.78 Mn |
| Jun 30, 2021 | -13.78 Mn |
| Mar 31, 2021 | -8.06 Mn |
| Mar 31, 2021 | -8.06 Mn |
| Dec 31, 2020 | -5.27 Mn |
| Dec 31, 2020 | -5.27 Mn |
| Sep 30, 2020 | -2.49 Mn |
| Sep 30, 2020 | -2.49 Mn |